Skip to main content
Equibles
VIR logo

VIR · Vir Biotechnology, Inc. · Webcasts, Transcripts & Audio

Track VIR — free

Use VIR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VIR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.75 +0.18 (+1.56%) Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.88B
Shares
169.22M
Volume · Oct 28 528.77K Avg daily vol (3M) 1.91M

Vir Biotechnology, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Vir Biotechnology, Inc. (VIR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-04
Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-05
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
Confident tone Hepatitis Delta registrational program (Eclipse trials) HDV disease awareness, testing and diagnosis Oncology pipeline - VIR-5500 PSMA T-cell engager
Revenue
$238.95M
▲ 19582.5% YoY
Diluted EPS
$0.47
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-12
Vir Biotechnology, Inc. (VIR) May 12, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Confident tone Astellas collaboration / VIR-5500 prostate cancer Hepatitis delta (tobevibart + elebsiran) and ECLIPSE trials Other T cell engager pipeline (VIR-5818, VIR-5525)
Revenue
−$29,000
▼ 101% YoY
Diluted EPS
$-0.85
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-23
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Confident tone Strategic collaboration with Astellas Dose escalation and therapeutic index optimization Pro-X10 platform validation
Revenue
$64.07M*
▲ 417.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript
Confident tone Eclipse Phase 3 Hepatitis Delta Program VIR-5500 PSMA T-cell Engager Solstice Phase 2 Data and ASLD Presentation
Revenue
$240,000
▼ 89.9% YoY
Diluted EPS
$-1.17
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript
Confident tone T Cell Engager Oncology Portfolio (PRO-XTEN) Hepatitis Delta / ECLIPSE Program PSMA / VIR-5500 Prostate Cancer
Revenue
$1.21M
▼ 60.5% YoY
Diluted EPS
$-0.80
Gross margin
99.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript
Confident tone Hepatitis Delta (Eclipse Phase 3) Program Pro-X10 Oncology T-cell Engager Platform Hepatitis B Program
Revenue
$3.03M
▼ 94.6% YoY
Diluted EPS
$-0.88
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript
Confident tone T-cell engager oncology platform and PRO-XTEN Hepatitis B functional cure and partnership strategy Hepatitis delta (HDV) program and ECLIPSE Phase III
Revenue
$12.37M*
▼ 26.3% YoY
Gross margin
94.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
Confident tone Sanofi licensing deal and T-cell engagers Hepatitis B (HBV) functional cure program Upcoming investor events and AASLD data
Revenue
$2.38M
▼ 9.8% YoY
Diluted EPS
$-1.56
Gross margin
97.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript
Confident tone Sanofi license agreement / masked T-cell engagers Cancer therapeutics landscape and unmet need Revised 2024 expense guidance
Revenue
$3.08M
▼ 19% YoY
Diluted EPS
$-1.02
Gross margin
98.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
Positive tone Hepatitis delta / SOLSTICE trial Hepatitis B functional cure / MARCH trial Regulatory engagement and Phase III planning
Revenue
$56.38M
▼ 10.5% YoY
Diluted EPS
$-0.48
Gross margin
99.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Call Transcript
Confident tone Financial position and capital allocation Leadership transition (CMO departure) Influenza antibodies / GSK collaboration termination
Revenue
$16.79M*
▼ 66% YoY
Gross margin
95.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Vir Biotechnology, Inc. (VIR) Q3 2023 Earnings Call Transcript
Revenue
$2.64M
▼ 99.3% YoY
Diluted EPS
$-1.22
▼ 193.8% YoY
Gross margin
98.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Vir Biotechnology, Inc. (VIR) Q2 2023 Earnings Call Transcript
Revenue
$3.80M
Diluted EPS
$-1.45
Gross margin
99.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–15 of 15 webcasts
Key facts CIK 1706431 CUSIP 92764N102 13F (30d) 43 filings 43 filers Visit website Investor relations